{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:31:47Z","timestamp":1761823907335},"reference-count":97,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":1469,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Visceral Surgery"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.jviscsurg.2017.05.004","type":"journal-article","created":{"date-parts":[[2017,6,10]],"date-time":"2017-06-10T16:16:59Z","timestamp":1497111419000},"page":"185-195","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["What is the impact of neoadjuvant chemoradiation on outcomes in gastro-intestinal cancer?"],"prefix":"10.1016","volume":"154","author":[{"given":"C.","family":"Mariette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Brouquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Tzanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Laurenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"de la Rochefordi\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Piessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sa Cunha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Penna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0490","unstructured":"Th\u00e9saurus national de canc\u00e9rologie digestive. http:\/\/www.tncd.org\/."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0495","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for esophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0500","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2013.53.6532","article-title":"Surgery alone versus chemoradiotherapy followed by surgery for stage\u00a0I and II esophageal cancer: final analysis of randomized controlled phase\u00a0III trial FFCD\u00a09901","volume":"32","author":"Mariette","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0505","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0510","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1470-2045(11)70142-5","article-title":"Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal carcinoma: an updated meta-analysis","volume":"12","author":"Sjoquist","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0515","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1056\/NEJMoa010580","article-title":"Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer","volume":"345","author":"Kapiteijn","year":"2001","journal-title":"N. Engl J Med"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0520","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1470-2045(11)70097-3","article-title":"Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomized controlled TME trial","volume":"12","author":"Gijn","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0525","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa060829","article-title":"Chemotherapy with preoperative radiotherapy in rectal cancer","volume":"355","author":"Bosset","year":"2006","journal-title":"N Engl J Med"},{"issue":"11.","key":"10.1016\/j.jviscsurg.2017.05.004_bib0530","article-title":"Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase\u00a0III randomized clinical trial","volume":"107","author":"Allegra","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0535","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S1470-2045(15)00159-X","article-title":"Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO\/ARO\/AIO-04 study): final results of the multicentre, open-label, randomised, phase\u00a03 trial","volume":"16","author":"R\u00f6del","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0540","series-title":"Current surgical therapy","first-page":"241","article-title":"Tumors of the anal region","author":"Ayscue","year":"2008"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0545","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF02586980","article-title":"Combined therapy for cancer of the anal canal: a preliminary report","volume":"17","author":"Nigro","year":"1974","journal-title":"Dis Colon Rectum."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0550","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","article-title":"Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0555","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0560","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/A:1011107105538","article-title":"High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase\u00a0II study","volume":"12","author":"Peiffert","year":"2001","journal-title":"Ann Oncol."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0565","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s10350-008-9361-x","article-title":"Abdominoperineal resection for anal cancer","volume":"51","author":"Mariani","year":"2008","journal-title":"Dis Colon Rectum."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0570","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10350-007-9125-z","article-title":"Squamous-cell carcinoma of the anal canal: predictors of treatment outcome","volume":"51","author":"Roohipour","year":"2008","journal-title":"Dis Colon Rectum."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0575","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/annonc\/mdu138","article-title":"European cancer mortality predictions for the year\u00a02014","volume":"25","author":"Malvezzi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0580","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0585","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0590","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0595","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0600","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0605","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2013.50.7657","article-title":"Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study","volume":"32","author":"Valle","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0610","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4\u00a0months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0615","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1245\/s10434-009-0408-6","article-title":"Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement","volume":"16","author":"Callery","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0620","doi-asserted-by":"crossref","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"7","author":"Gillen","year":"2010","journal-title":"Plos Med"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0625","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/SLA.0000000000000991","article-title":"Impact of neoadjuvant chemoradiation on lymph node status in esophageal cancer: post hoc analysis of a randomized controlled trial","volume":"261","author":"Robb","year":"2015","journal-title":"Ann Surg."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0630","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/SLA.0000000000000965","article-title":"Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival","volume":"260","author":"Koen Talsma","year":"2014","journal-title":"Ann Surg."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0635","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jtcvs.2007.10.082","article-title":"En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma","volume":"135","author":"Rizzetto","year":"2008","journal-title":"J Thorac Cardiovasc Surg."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0640","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1245\/s10434-009-0819-4","article-title":"The roles of neoadjuvant radiotherapy and lymphadenectomy in the treatment of esophageal adenocarcinoma","volume":"17","author":"Solomon","year":"2010","journal-title":"Ann Surg Oncol."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0645","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jviscsurg.2014.09.001","article-title":"The role for surgery when primary (radio)chemotherapy treatment of gastro-intestinal tumors results in clinical complete response","volume":"151","author":"Piessen","year":"2014","journal-title":"J Visc Surg."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0650","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/SLA.0000000000000228","article-title":"Is there a role for surgery for patients with a complete clinical response after chemoradiation for esophageal cancer? An intention-to-treat case-control study","volume":"258","author":"Piessen","year":"2013","journal-title":"Ann Surg."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0655","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000351999","article-title":"Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation","volume":"85","author":"Taketa","year":"2013","journal-title":"Oncology."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0660","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s11605-013-2269-3","article-title":"Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus: is surgery always necessary","volume":"17","author":"Castoro","year":"2013","journal-title":"J Gastrointest Surg."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0665","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.athoracsur.2013.12.026","article-title":"Does timing of surgical procedure after neoadjuvant chemoradiation affect outcomes in esophageal cancer?","volume":"97","author":"Tessier","year":"2014","journal-title":"Ann Thorac Surg."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0670","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.athoracsur.2011.05.021","article-title":"Does the timing of esophagectomy after chemoradiation affect outcome?","volume":"93","author":"Kim","year":"2012","journal-title":"Ann Thorac Surg."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0675","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/SLA.0b013e3181fc7f86","article-title":"Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome?","volume":"252","author":"Ruol","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0680","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1245\/s10434-013-3139-7","article-title":"Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?","volume":"20","author":"Chiu","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"18S","key":"10.1016\/j.jviscsurg.2017.05.004_bib0685","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1200\/jco.2006.24.18_suppl.3527","article-title":"Sphincter preserving surgery after preoperative treatment for ultra-low rectal carcinoma. A French multicenter prospective trial: GRECCAR\u00a01","volume":"24","author":"Rouanet","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0690","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s00268-014-2930-3","article-title":"Changing operative strategy from abdominoperineal resection to sphincter preservation in T3\u00a0low rectal cancer after downstaging by neoadjuvant chemoradiation: a preliminary report","volume":"39","author":"Madbouly","year":"2015","journal-title":"World J Surg"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0695","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/codi.13240","article-title":"Controversies in the management of rectal cancer. A survey of French surgeons, oncologists and radiotherapists","volume":"18","author":"Lefevre","year":"2016","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0700","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage\u00a00 distal rectal cancer following chemoradiation therapy: long-term results","volume":"240","author":"Habr-Gama","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0705","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/bjs.8732","article-title":"Critical appraisal of the \u201cwait and see\u201d approach in rectal cancer for clinical complete responders after chemoradiation","volume":"99","author":"Glyne Jones","year":"2012","journal-title":"Br J Surg"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0710","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1200\/JCO.2011.37.7176","article-title":"Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer","volume":"29","author":"Maas","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0715","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/SLA.0b013e3182759f1c","article-title":"Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy","volume":"256","author":"Smith","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0720","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(15)00120-5","article-title":"High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study","volume":"16","author":"Appelt","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0725","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/bjs.9809","article-title":"Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study)","volume":"102","author":"Verseveld","year":"2015","journal-title":"Br J Surg"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0730","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S1470-2045(15)00215-6","article-title":"Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase\u00a02 trial","volume":"16","author":"Garcia-Aguilar","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0735","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10350-003-0062-1","article-title":"Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection","volume":"47","author":"Moore","year":"2004","journal-title":"Dis Colon Rectum."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0740","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1245\/s10434-008-9892-3","article-title":"An interval >7\u00a0weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer","volume":"15","author":"Tulchinsky","year":"2008","journal-title":"Ann Surg Oncol."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0745","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/SLA.0b013e3181b91e63","article-title":"Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer","volume":"250","author":"Kalady","year":"2009","journal-title":"Ann Surg."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0750","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00384-014-2082-9","article-title":"A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer","volume":"30","author":"Petrelli","year":"2015","journal-title":"Int J Colorectal Dis."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0755","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.67.6049","article-title":"Effect of interval (7 or 11\u00a0weeks) between neoadjuvant chemoradiotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6)","author":"Lefevre","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0760","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1245\/s10434-012-2485-1","article-title":"Abdominoperineal resection for squamous-cell anal carcinoma: survival and risk factors for recurrence","volume":"19","author":"Lefevre","year":"2012","journal-title":"Ann Surg Oncol."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0765","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0021-7697(08)74312-6","article-title":"Complete (R0) resection is the only valid prognostic factor in abdominoperineal resection for recurrent cancer of the anal canal","volume":"145","author":"Rouquie","year":"2008","journal-title":"J Chir (Paris)"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0770","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/jso.23283","article-title":"Salvage abdominoperineal resection for anal cancer following chemoradiation: a proposed scoring system for predicting postoperative survival","volume":"107","author":"Correa","year":"2013","journal-title":"J Surg Oncol."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0775","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF02303552","article-title":"Salvage abdominoperineal resection following combined chemotherapy and radiotherapy for epidermoid carcinoma of the anus","volume":"1","author":"Ellenhorn","year":"1994","journal-title":"Ann Surg Oncol."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0780","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1007\/BF02237294","article-title":"Results of salvage abdominoperineal resection for anal cancer after radiotherapy","volume":"41","author":"Pocard","year":"1998","journal-title":"Dis Colon Rectum."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0785","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1091-255X(01)80066-4","article-title":"Results of salvage abdominoperineal resection for recurrent anal carcinoma following combined chemoradiation therapy","volume":"5","author":"van der Wal","year":"2001","journal-title":"J Gastrointest Surg."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0790","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1046\/j.1365-2168.2002.02231.x","article-title":"Salvage abdominoperineal resection in anal epidermoid cancer","volume":"89","author":"Nilsson","year":"2002","journal-title":"Br J Surg."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0795","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s10350-004-0548-5","article-title":"Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy","volume":"47","author":"Akbari","year":"2004","journal-title":"Dis Colon Rectum."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0800","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1007\/s00268-005-7957-z","article-title":"Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer","volume":"29","author":"Ferenschild","year":"2005","journal-title":"World J Surg."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0805","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s10350-004-0746-1","article-title":"Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer","volume":"48","author":"Ghouti","year":"2005","journal-title":"Dis Colon Rectum."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0810","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/bjs.4908","article-title":"Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer","volume":"92","author":"Renehan","year":"2005","journal-title":"Br J Surg."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0815","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1245\/s10434-006-9221-7","article-title":"Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal","volume":"14","author":"Mullen","year":"2007","journal-title":"Ann Surg Oncol."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0820","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1245\/s10434-007-9491-8","article-title":"Outcomes of salvage surgery for squamous cell carcinoma of the anal canal","volume":"14","author":"Schiller","year":"2007","journal-title":"Ann Surg Oncol."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0825","first-page":"839","article-title":"Salvage surgery for anal canal carcinomas","volume":"91","author":"Sideris","year":"2004","journal-title":"Bull Cancer."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0830","first-page":"21527","article-title":"Salvage surgery for residual primary and locally recurrent anal squamous cell carcinoma after chemoradiotherapy in HIV-positive individuals","author":"Cunin","year":"2014","journal-title":"Ann Surg Oncol."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0835","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"Folfirinox versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0840","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1634\/theoncologist.2012-0435","article-title":"Folfirinox in locally advanced pancreatic cancer: the Massachusetts general hospital cancer center experience","volume":"18","author":"Faris","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0845","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/jso.23392","article-title":"Outcomes with Folfirinox for borderline resectable and locally unresectable pancreatic cancer","volume":"108","author":"Boone","year":"2013","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0850","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1634\/theoncologist.2013-0273","article-title":"Neoadjuvant Folfirinox for borderline resectable pancreas cancer: a new treatment paradigm?","volume":"19","author":"Christians","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0855","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1245\/s10434-015-4647-4","article-title":"Folfirinox induction therapy for stage\u00a03 pancreatic adenocarcinoma","volume":"22","author":"Sadot","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0860","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1245\/s10434-014-3898-9","article-title":"Folfirinox for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort","volume":"22","author":"Marthey","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"Suppl. 3","key":"10.1016\/j.jviscsurg.2017.05.004_bib0865","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1245\/s10434-015-4783-x","article-title":"Pathologic major response after Folfirinox is prognostic for patients secondary resected for borderline or locally advanced pancreatic adenocarcinoma: an Ageo-French, prospective, multicentric cohort","volume":"22","author":"Pietrasz","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0870","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3109\/0284186X.2013.771821","article-title":"Safety and efficacy of neoadjuvant Folfirinox treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma","volume":"52","author":"Tinchon","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0875","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/MPA.0000000000000314","article-title":"Folfirinox-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies","volume":"44","author":"Petrelli","year":"2015","journal-title":"Pancreas"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0880","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","article-title":"Radiological and surgical implications of neoadjuvant treatment with Folfirinox for locally advanced and borderline resectable pancreatic cancer","volume":"261","author":"Ferrone","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0885","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/gut.2003.025080","article-title":"Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis","volume":"53","author":"Fiorica","year":"2004","journal-title":"Gut."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0890","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/bjs.9418","article-title":"Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers","volume":"101","author":"Kumagai","year":"2014","journal-title":"Br J Surg."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0895","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/SLA.0000000000000955","article-title":"Impact of neoadjuvant chemoradiotherapy on postoperative outcomes after esophageal cancer resection: results of a European multicenter study","volume":"260","author":"Gronnier","year":"2014","journal-title":"Ann Surg."},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0900","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1200\/JCO.2014.59.9092","article-title":"Salvage surgery after chemoradiotherapy in the management of esophageal cancer: is it a viable therapeutic option?","volume":"33","author":"Markar","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0905","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1245\/s10434-015-4423-5","article-title":"High-grade toxicity to neoadjuvant treatment for upper gastrointestinal carcinomas: what is the impact on perioperative and oncologic outcomes?","volume":"22","author":"Robb","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0910","first-page":"5","article-title":"Intensity-modulated radiation therapy (IMRT) vs 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications","volume":"26","author":"Arbea","year":"2010","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0915","first-page":"910956","article-title":"Does preoperative radio (chemo) therapy increase anastomotic leakage in rectal cancer surgery? A meta-analysis of randomized controlled trials","author":"Changjang","year":"2014","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0920","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1245\/s10434-012-2827-z","article-title":"Effect of preoperative radio (chemo) therapy on long-term functional outcome in rectal cancer patients: a systematic review and meta-analysis","volume":"20","author":"Loos","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0925","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/SLA.0b013e31815c29ff","article-title":"Long-term results of intersphincteric resection for low rectal cancer","volume":"246","author":"Chamlou","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0930","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2005.14.779","article-title":"Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients","volume":"23","author":"Peeters","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0935","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1200\/JCO.2005.05.256","article-title":"Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial","volume":"23","author":"Marijnen","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0940","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.ejso.2015.07.003","article-title":"Neoadjuvant therapy abolishes the functional benefits of a larger rectal remnant, as measured by magnetic resonance imaging after restorative rectal cancer surgery","volume":"41","author":"Bondeven","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0945","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ijsu.2013.05.004","article-title":"How should perineal wounds be closed following abdominoperineal resection in patients post-radiotherapy \u2013 primary closure or flap repair? Best evidence topic (BET)","volume":"11","author":"Howell","year":"2013","journal-title":"Int J Surg"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0950","first-page":"550","article-title":"Perineal hernia after abdominoperineal amputation. Role of epiploplasty and\/or irradiation","volume":"129","author":"Berthoux","year":"1992","journal-title":"J Chir (Paris)"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0955","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/DCR.0000000000000161","article-title":"Incisional negative pressure wound therapy decreases the frequency of postoperative perineal surgical site infections: a cohort study","volume":"57","author":"Chadi","year":"2014","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0960","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/DCR.0b013e31819f2a4b","article-title":"Oncologic and functional results after abdominoperineal resection plus pseudocontinent perineal colostomy for epidermoid carcinoma of the anus","volume":"52","author":"Go\u00e9r\u00e9","year":"2009","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0965","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/jso.22105","article-title":"Impact of perineal pseudocontinent colostomy on perineal wound healing after abdominoperineal resection","volume":"105","author":"Dumont","year":"2012","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.jviscsurg.2017.05.004_bib0970","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1245\/ASO.2006.02.003","article-title":"Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy","volume":"13","author":"Cheng","year":"2006","journal-title":"Ann Surg Oncol"}],"container-title":["Journal of Visceral Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878788617300474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878788617300474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T21:42:30Z","timestamp":1623534150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878788617300474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1878788617300474"],"URL":"https:\/\/doi.org\/10.1016\/j.jviscsurg.2017.05.004","relation":{},"ISSN":["1878-7886"],"issn-type":[{"value":"1878-7886","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What is the impact of neoadjuvant chemoradiation on outcomes in gastro-intestinal cancer?","name":"articletitle","label":"Article Title"},{"value":"Journal of Visceral Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jviscsurg.2017.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}